The SPIN works in close collaboration with National Representatives, gathering the representatives of the national psoriasis groups who participate to the network. We currently surveying in order to include key opinion leaders on atopic dermatitis at the national level.
SPIN National Representatives are in a privileged position to relay the information about SPIN’s projects, surveys and events at the national level. They have kindly accepted to be the national contact for all kind of collaborations, especially to promote the development of the network’s activities and the exchanges on psoriasis and atopic dermatitis all around the world. Each representative is responsible for the coordination of international collaborations between his or her country and the others, and of course for the participation to the projects around psoriasis and atopic dermatitis at the national level.
SPIN National Representatives will be solicited for input in the organisation of the scientific programme of the SPIN Congress taking place every three years. During the Congress, the National Representatives shall meet to foresee the next Congress and to choose the national or regional group that will be responsible for the scientific organisation of the following Congress.
Please find here below the list of SPIN National Representatives (this list shall be updated regularly):
Aomar AMMAR-KHODJA - Algeria
Nélida RAIMONDO- Argentina
Pablo FERNÁNDEZ-PEÑAS - Australia
Patrick BRUNNER- Austria
Uladzimir ADASKEVICH - Belarus
Michel DE LA BRASSINNE - Belgium
Félix ATADOKPEDE - Benin
Juan Carlos DIEZ DE MEDINA - Bolivia
Asja PROHIC - Bosnia and Herzegovina
Luna AZULAY - Brazil
Nikolai TSANKOV - Bulgaria
Fatou BARRO TRAORE - Burkina Faso
Christine MADENGUE - Cameroon
Chih-ho HONG - Canada
Claudia DE LA CRUZ - Chile
Min ZHENG - China
Chih-Hung LEE - Chinese Taipei
Cesar GONZALEZ A. - Colombia
Laura ALVAREZ MORALES - Costa Rica
Abdoulaye SANGHARE - Cote d’Ivoire
Romana CEOVIC - Croatia
Orestes BLANCO G. - Cuba
Jana HERCOGOVA - Czech Republic
Robert GNIADECKI - Denmark
Lars IVERSEN - Denmark
Alexandra ESPINAL - Dominican Republic
Emad ELGAMAL - Egypt
Leana QUINTANILLA - El Salvador
Jaime MARTINEZ LOPEZ - El Salvador
Külli KINGO- Estonia
Tarja MALKONEN - Finland
Carle PAUL - France
Sophie CONIQUET - Gabon
Nino CHIJAVADZE - Georgia
Tsira LEONIDZE - Georgia
Matthias AUGUSTIN - Germany
Christina ANTONIOU - Greece
Mohamed CISSE - Guinea
Ligia RAMOS - Honduras
Patricia MEJIAS - Honduras
Rolland Gyulai - Hungary
Jon Hjaltalin OLAFSSON - Iceland
Alur S. KUMAR - India
Benny E. WIRYADI- Indonesia
Omid ZARGARI - Iran
Brian KIRBY - Ireland
Lev PAVLOVSKY - Israel
Luigi NALDI - Italy
Hidemi NAKAGAWA - Japan
Laith AKKASH - Jordan
Joo Heung Lee- Korea
Nawaf AL MUTAIRI - Kuwait
Andris RUBINS - Latvia
Abdul Ghani KIBBI - Lebanon
Gamal A. DUWEB - Libya
Skaidra VALIUKEVICIENE - Lithuania
Emilija MANASIEVSKA - Macedonia
Azura Mohd AFFANDI- Malaysia
Ousmane FAYE - Mali
Michael BOFFA - Malta
Mamadou BALL - Mauritania
Boris NEDELCIUC - Moldova
Fatima Zahra MERNISSI- Morocco
Phyllis I. SPULS - Netherlands
Jorge NEIRA - Nicaragua
Ousmane KONATE - Niger
Abel Nze ONUNU - Nigeria
Riad MASHAL - Palestine
Giuliana CASTRO - Peru
Maria Lorna FREZ - Philippines
Jacek SZEPIETOWSKI - Poland
Hugo OLIVEIRA - Portugal
Hassan RIAD - Qatar
George-Sorin TIPLICA - Romania
Nikolay POTEKAEV- Russia
Serge SKREK- Russia
Iqbal A. BUKHARI - Saudi Arabia
Fatimata LY - Senegal
Ljiljana MEDENICA - Serbia
Colin THENG - Singapore
Slavomir URBANCEK - Slovakia
Tomaz LUNDER - Slovenia
Luis PUIG - Spain
Mona STAHLE - Sweden
Nikhil YAWALKAR - Switzerland
Fouz HASSAN - Syria
Pravit ASAWANONDA - Thailand
Vincent Pitche - Togo
Nejib DOSS - Tunisia
Mehmet Ali GURER - Turkey
Fayza AL ALI- United Arab Emirates
Christopher GRIFFITHS - United Kingdom
Mark LEBWOHL - United States of America
Oleksandr LITUS - Ukraine
Carlos CARMONA - Uruguay
Erika PAEZ - Venezuela
Alfredo LANDER - Venezuela
Aiman ALSHAMI - Yemen
- 2019/08/12 Focus on...Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...News from our SPIN Columbian members
- 2019/05/21 Focus on...SPIN2019 is now available on your screen!
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2019/04/17 Focus on...Do not miss Spin Congress 2019 highlights
News from the web office
- 2017/06/05PIN becomes SPIN - Skin Inflammation & Psoriasis International Network
- 2016/10/29PSO 2016 Congress - Webcasts Available!
- 2016/05/26PIN Survey on Phototherapy
- 2016/02/20PIN Study on Therapeutic Patient Education
- 2016/02/19World Directory of Psoriasis Medical Resources - February 2016 Update
- 2019/04/18 Focus on...SPIN Congress 2019 in Paris coming soon
- 2018/07/16SPIN Symposium at the Spring continental meeting - Tehran, 25-27 April 2018
- 2018/02/222nd National Meeting of the Egyptian Society for Psoriasis
- 2018/02/211st Psoriasis Symposium - Sarajevo 2017
- 2017/06/2815th São Paulo Meeting of Psoriasis and Vitiligo
News from medical groups
- 2018/04/183rd Turkish National Psoriasis Symposium
- 2017/06/21Brazilian Center for Psoriasis Studies joins SPIN!
- 2017/06/21Costa Rica Psoriasis Group - Meet them!
- 2017/02/02Works of the 1st Senegalese Psoriasis Day published!
- 2016/07/29Swiss S1 Guidelines for Systemic treatment of psoriasis vulgaris
News from patients associations
- 2017/02/08France Psoriasis - 2016 World Psoriasis Day
- 2016/05/26Senegal Patients Association joins PIN!
- 2015/08/04Epidermia Greece: a new partner association of PIN
- 2015/08/01Canadian Association of Psoriasis Patients joins PIN!
- 2015/04/09AEPSO Argentina launches digital map to find people with psoriasis in the country
Recent publications on Psoriasis and Atopic Dermatitis
JAK-inhibitors in dermatology: current evidence and future applications.
J Dermatolog Treat. 2019 Nov , 30, (7):648-658.
The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is a ubiquitous intracellular signaling network. Selective JAK-inhibitors have anti-inflammatory properties and have been approved in many countries for the treatment of rheumatoid arthritis (tofacitinib, baricitinib) and myelofibrosis or polycythemia vera (ruxolitinib). The aim of the publication was to summarize and critically analyze the efficacy and safety of JAK-inhibitors in skin diseases, such (...)see on pubmed
Patient preferences for attributes of topical anti-psoriatic medicines.
J Dermatolog Treat. 2019 Nov , 30, (7):659-663.
Patient preferences should be considered when prescribing topical treatments to drive up adherence and improve clinical outcomes. The aim of this work was to identify the most important attributes of topical medicines for psoriasis treatment in the patients' view, and explore the sociodemographic and clinical determinants of these preferences. A questionnaire for the evaluation of the relevancy given to specific attributes of topical medicines used for psoriasis treatment was developed (...)see on pubmed
Salidroside inhibits MAPK, NF-κB, and STAT3 pathways in psoriasis-associated oxidative stress via SIRT1 activation.
Redox Rep.. 2019 Dec , 24, (1):70-74.
To unveil the role of SIRT1 in limiting oxidative stress in psoriasis and to further discuss the therapeutic prospects of salidroside in psoriasis. Literature from 2002 to 2019 was searched with "psoriasis", "oxidative stress", "SIRT1", "salidroside" as the key words. Then, Oxidative stress in psoriasis and the role of SIRT1 were summarized and the potential role of salidroside in the disease was speculated. Oxidative stress might contribute to the pathogenesis of psoriasis. High levels (...)see on pubmed
A case of infective endocarditis associated with atopic dermatitis perioperatively treated with dupilumab.
J Dermatolog Treat. 2019 Nov , 30, (7):674-676.
Several case reports and reviews support a relationship between atopic dermatitis (AD) and infective endocarditis (IE). Here, we present a case of severe AD suspected of causing IE. A 21-year-old man with severe AD was admitted to our hospital due to unidentified fever, syncope, and headache. He was diagnosed with IE with cerebral embolism and mitral regurgitation. Before elective cardiac surgery, he was subcutaneously administered dupilumab for 2 months to control AD. Dupilumab improved (...)see on pubmed
Effect of cinnamamides on atopic dermatitis through regulation of IL-4 in CD4 cells.
J Enzyme Inhib Med Chem. 2019 Dec , 34, (1):613-619.
This study aimed to evaluate the effects of cinnamamides on atopic dermatitis (AD) and the mechanisms underlying these effects. To this end, the actions of two cinnamamides, (E)-3-(4-hydroxyphenyl)-N-phenylethyl acrylamide (NCT) and N-trans-coumaroyltyramine (NCPA), were determined on AD by orally administering them to mice. Oral administration of the cinnamamides ameliorated the increase in epidermal and dermal thickness as well as mast cell infiltration. Cinnamamides suppressed serum (...)see on pubmed
Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Artif Cells Nanomed Biotechnol. 2019 Dec , 47, (1):3540-3547.
Allergen-specific immunotherapy is widely used for allergic rhinitis and asthma treatment worldwide. This study explored the efficacy and safety of sublingual immunotherapy (SLIT) with the extracts of ( Drops) on house dust mites (HDM)-induced atopic dermatitis (AD). 239 patients with HDM-induced AD were recruited and exposure to a multi-centre, randomized, double-blind, and placebo-controlled clinical trials for 36 weeks, which were randomly divided into placebo and sublingual Drops (...)see on pubmed